ACUTE LEUKEMIAS XVIII
Biology and Treatment Strategies

Munich, Germany - February 21-24, 2021

International Symposium

Industry Sponsored Satellite Symposia

(Companies in alphabetical order)

 

Abbvie Deutschland GmbH (Gold Circle Member)

Satellite Symposium II: Sunday, February 24, 2019: 18.15 -19.15 (Lecture Hall III/IV)

"Changing the goals in AML: Optimizing Therapeutic Approaches for the Older Patients"

18.15-18.25
U. Platzbecker, Leipzig, DE

Welcome and introduction

  • Setting the scene
  • The changing landscape in AML
  • Defining treatment goals and therapeutic approaches in the older patient with AML

18.25-18.40
NN

Emerging agents for the treatment of patients with AML

  • Overview of potential targets/pathways
  • Targeted therapies – FLT3 and IDH inhibitors (focus on agents that are currently available, or will be available in the near-future)
  • BCL-2 inhibition with venetoclax

18.40-18.55
U. Platzbecker, Leipzig, DE

Strategies to overcome resistance

  • Mechanisms of resistance to conventional therapy
  • Role of LSCs in resistance and relapse (data on overexpression of BCL-2 in LSCs to be included)
  • Combination strategies to prevent and overcome resistance (e.g. HMA + targeted agents)

18.55-19.05
NN

From bench to bedside: Practical considerations for the older patient with AML

  • Management of adverse events
  • Patient compliance
  • Expert opinion

19.05-19.10
Audience Q&A

19.10-19.15
Summary and Close

 

Amgen GmbH (Gold Circle Member)

Satellite Symposium I: Sunday, February 24, 2019: 17.00 -18.00 (Lecture Hall III/IV)

"Targeted Therapy of Acute Leukemia: Present Achievements and Future Potential"

17.00-17.05
M.Topp, Würzburg, DE
Welcome and Introduction

17.05-17.30
M. Topp, Würzburg, DE
The Present: T-Cell Engaging Immunotherapy for ALL

17.30-17.55
M. Subklewe, Munich, DE
The Future: Bispecific Antibody Constructs for the Treatment of AML

17.55-18.00
M. Subklewe, Munich, DE
Closing Remarks

 

Astellas Pharma (Gold Circle Member)

Satellite Symposium VI: Tuesday, February 26, 2019: 13.00 -14.00 (Lecture Hall III/IV)

"Progress in AML: The Present and the Future"

Chair:
L. Bullinger, Berlin, DE

13.00-13.05
L. Bullinger, Berlin, DE
Welcome and Introduction

13.05-13.20
K. Götze, Munich, DE
Progress in AML: The Present

13.25-13.45
Th. Schröder, Düsseldorf, DE
Progress in AML: The Future

13.45-14.00
L. Bullinger, Berlin, DE
Discussion and Conclusion - All

  

Celgene GmbH (Gold Circle Member)

Satellite Symposium VII: Tuesday, February 26, 2019: 16.30 - 17.30 (Lecture Hall III/IV)

"Deciphering AML complexities: Prognosis and Treatment"

Chair:
K. Metzeler, Munich, DE

16.30-16.35
K. Metzeler, Munich, DE
Welcome and Introduction

16.35-17.00
K. Döhner, Ulm, DE
How do Genetics of AML Patients influence Prognosis, Treatment Strategies and Follow-Up Today and Tomorrow?

17.00-17.25
H. Dombret, Paris, F
What Expectations do we have of AML Treatment beyond Complete Remission?

17.25-17.30
Discussion and Close

     

Daiichi Sankyo (Gold Circle Member)

Satellite Symposium IV: Monday, February 25, 2019: 17.00 -18.00 (Lecture Hall III/IV)

"FLT3/Targeted Therapy / Future of AML Therapy"

Chair:
W. Hiddemann, Munich, DE

17.00-17.05
W. Hiddemann, Munich DE
Welcome and Introduction

17.05-17.25
R. Schlenk, Heidelberg, DE
Targeted Therapy in AML: What do the Guidelines tell us?

17.25-17.45
M.J. Levis, Baltimore, USA
Targeted Therapy in AML: Where does the Science guide us?

17.50-18.00
W. Hiddemann, Munich, DE
Panel Discussion and Closing Remarks

  

Jazz Pharmaceuticals Germany GmbH (Gold Circle Member)

Satellite Symposium III: Monday, February 25, 2019: 12.45 - 13.45 (Lecture Hall III/IV)

"High-Risk AML: WHO Knows? Improving Outcomes in these Patients"

12.45-12.50
L. Bullinger, Berlin, DE
Welcome and Introduction

12.50-13.10
L. Bullinger, Berlin, DE
Diagnosing High-Risk AML: *WHO and What?

  • Clinical and Biological Heterogeneity of AML (Cytogenetics and Genomics)
  • Overview of different classification systems
  • Therapy related AML (t-AML)
    o Pathogenesis, clinical and genomic features, prognosis
  • AML with Myelodysplasia Related Changes (AML-MRC)
    o WHO 2016 classification
    o Pathogenesis, clinical and genomic features, prognosis

13.10-13.30
M.S.Tallman, New York, NY, USA
Improving Outcomes in High-Risk AML

  • Patient Case Study
  • trial Data Included Throughout Presentation

13.30-13.45
Q & A

        

Pfizer GmbH (Gold Circle Member)

Satellite Symposium VIII: Tuesday, February 26, 2019: 17.45 - 18.45 (Lecture Hall III/IV)

"Changing Treatment Landscape in AML"

Chair:
L. Bullinger, Berlin, DE

17.45-17.50
L. Bullinger, Berlin, DE
Welcome

17.50-18.10
M. Subklewe, Munich, DE
Gemtuzumab Ozogamicin in de novo AML

18.10-18.15
Q & A

18.15-18.35
C. Müller-Tidow, Heidelberg, DE
Emerging Treatment Strategies in AML

18.35-18.40
Q & A

18.40-18.45
L. Bullinger, Berlin, DE
Conclusion

  

Vector Therapeutics (Bronze Circle Member)

EVENING SYMPOSIUM: Monday, February 25, 2019: 20.00-21.00 LeMeridien
(A free-of-charge Shuttle Bus Service will be available for all participants joining the Evening Symposium at LeMeridien after the end of Satellite V starting from the symposium venue (Back entrance Hörsaaltrakt; Details will be announced on site)

"Preventing AML Relapse: The Role of Immunotherapy"

Chair:
W. Hiddemann, Munich, DE

19.30 -20.00
Welcome Reception – Drinks & Food

20.00 -20.10
W. Hiddemann, Munich, DE
Introduction

20.10-20.25
Anna Martner, Gothenburg, SE
Highlights & Key Results: Immune Activation during Immunotherapy with Ceplene/IL-2 Implications for Relapse risk and Survival in AML

20.25-20.40
Kristoffer Hellstrand, Gothenburg, SE
Highlights & Key results: Relapse Prevention by Ceplene/IL-2 in Molecular Subgroups of AML

20.40 -21.00
W. Hiddemann, Munich, DE
Roundtable / Panel Discussion

CLOSING REMARKS

PLEASE REGISTER via: vectortherapeutics-symposium@iqvia.com